Skip to main content

DioGenix Raises $3.2M to Support Multiple Sclerosis Test Development

NEW YORK (GenomeWeb News) — DioGenix announced today that it raised $3.2 million in a private financing that will support an ongoing prospective clinical trial of its next generation sequencing-based multiple sclerosis test, MS Precise.

The financing involved both new and returning individual investors, the company said, including life sciences fund Nerveda, whose president, Cam Gallagher, is also chairman of DioGenix. Other investors were not named.

"DioGenix has achieved important development and business milestones that pave the way for its lead product to achieve additional clinical progress in 2014," Gallagher said in a statement.

According to DioGenix, the funding follows on interim results from the company's ongoing prospective clinical trial, which it hopes will validate the performance of the assay in identifying patients with MS at their first clinical presentation more accurately than current clinical assessment methods.

In previous studies, the company said, MSPrecise outperformed the current standard of care for cerebral spinal fluid analysis in patients suspected of having MS by almost two to one in terms of specificity with no loss of sensitivity.

DioGenix also announced it has established a new central laboratory, for which it is seeking CLIA certification in order to support future commercialization of the assay as a laboratory-developed test.

The company said it has also expanded a licensing arrangement with the University of Texas Southwestern Medical Center, making exclusive its license of its MSPrecise-related technology.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.